Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 3, 1996, Pages 268-274

  Goldberg, Michael R ^a   Lo, Man Wai ^a   Deutsch, Paul J ^a   Wilson, Susan E ^a   McWilliams, Edward J ^a   McCrea, Jacqueline B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450; DRUG METABOLITE; LOSARTAN; PHENOBARBITAL; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INDUCTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; ANTICONVULSANTS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; HUMANS; HYDROCORTISONE; HYPNOTICS AND SEDATIVES; IMIDAZOLES; LOSARTAN; MALE; MIXED FUNCTION OXYGENASES; PHENOBARBITAL; REFERENCE VALUES; SINGLE-BLIND METHOD; TETRAZOLES;

EID: 0029972753     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)80004-X     Document Type: Article

References (16)

1. Timmermans P, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens 1992;5(part 2):221S-35S.
2. Nelson E, Merrill D, Sweet C, et al. Efficacy and safety of oral MK-954 DuP 753, an angiotensin receptor antagonist, in essential hypertension. J Hypertens 1991;9(suppl 6):S468-9.
3. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-7.
4. Munafo A, Christen Y, Nussberger J, et al. Drug concentration-response relationship in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. CLIN PHARMACOL THER 1992;51:513-21.
5. Stearns RA, Miller RR, Doss GA, et al. The metabolism of DuP 753, a non-peptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos 1992;20:281-7.
6. Stearns RA, Chakravarty PK, Chen R, Chiu SHL. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of CYP2C and CYP3A subfamily members. Drug Metab Dispos 1995;23:207-15.
7. Goldberg MR, Lo MW, Bradstreet TE, Ritter MA, Högland P. Effects of cimetidine on the pharmacokinetics and pharmacodynamics of losartan. Eur J Clin Pharmacol [In press].
8. Park BK, Breckenridge AM. Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 1981;6:1-24.
9. MacDonald MG, Robinson DS. The effects of phenobarbital, chloral betaine, and glutethimide administration on warfarin plasma levels and hypoprothrombinemic responses in man. CLIN PHARMACOL THER 1969;10:80-4.
10. Ohnhaus E, Breckenridge AM, Park BK. Urinary excretion of 6-β-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 1989;36:39-46.
11. Ged C, Rouillon JM, Pichard L. The increase in urinary excretion of 6-β-hydroxycortisol as a marker of human hepatic cytochrome P450 IIIA induction. Br J Clin Pharmacol 1989;28:373-87.
12. Furtek CI, Lo MW. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr 1992;573:295-301.
13. Lam FC, Hung CR, Perrier DG. Estimation of variance for harmonic mean half-lives. J Pharm Sci 1985; 74:229-31.
14. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames, Iowa: Iowa State University Press, 1980: 234-5.
15. Steel RGD, Torrie JH. Principles and procedures of statistics, New York: McGraw-Hill, 1980:102-5.
16. Satterthwaite FE. An approximate distribution of estimates of variance components. Biometrics Bull 1946;2:110-4.